Carlyle Group Inc (CG) Stock Price Today
Aura AI Summary
Key Stats
- $12.96BMarket Cap
- 1,818,887Volume
- FinancialsSector
- $66.1252W High
- $35.7752W Low
- 113 DaysTypical Hold Time
- $25.18BEnterprise Value
- 3.85%Div Yield
- -Trading Activity
Track Carlyle Group Inc (CG) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Carlyle Group Inc has traded between a low of $35.77 and a high of $66.12, highlighting its annual price range. Buy and sell Carlyle Group Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Most Recent News
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Silence Therapeutics jumps 125% after $1.3B acquisition deal with Merck KGaA
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.